Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children108210.24287/j.1082CLINICAL OBSERVATIONSКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯResearch ArticleRelapsed lymphoblastic lymphoma in children and adolescents: current therapeutic options and a clinical case reportРецидивы лимфобластных лимфом у детей и подростков: возможности современных терапевтических опций и описание клинического случаяhttps://orcid.org/0000-0003-3218-1777RomanenkoE. S.РоманенкоЕ. С.
Russian Federation

Hematologist at the Oncohematology Department

врач-гематолог отделения онкогематологии

ekaterina.romanenko@dgoi.ruhttps://orcid.org/0000-0002-2574-1636VolchkovE. V.ВолчковЕ. В.
Russian Federation
ekaterina.romanenko@dgoi.ruhttps://orcid.org/0000-0002-8725-7532DyakonovaY. Y.ДьяконоваЮ. Ю.
Russian Federation
ekaterina.romanenko@dgoi.ruhttps://orcid.org/0000-0003-0520-5630ShelikhovaLarisa N.ШелиховаЛ. Н.
Russian Federation
ekaterina.romanenko@dgoi.ruhttps://orcid.org/0000-0002-4779-1896MyakovaN. V.МяковаН. В.
Russian Federation
ekaterina.romanenko@dgoi.ruThe Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России140420262511511560302202606022026Copyright ©; 2026, «D. Rogachev NMRCPHOI»Copyright ©; 2026, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2026«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/1082

Lymphoblastic lymphoma is the second most common type of non-Hodgkin lymphoma in children. Although outcomes are favorable after first-line therapy based on treatment regimens for acute lymphoblastic leukemia, the prognosis of patients with recurrent or refractory disease remains extremely poor, with overall survival rates of only about 50%. This article presents an analysis of factors contributing to resistance to therapy and highlights current strategies for the treatment of relapsed/refractory lymphoblastic lymphoma.

Лимфобластные лимфомы являются вторыми по частоте встречаемости среди неходжкинских лимфом детского возраста. Несмотря на успехи терапии первой линии, основанной на схемах лечения острых лимфобластных лейкозов, прогноз для пациентов с рецидивами или рефрактерным течением остается крайне неблагоприятным, показатели общей выживаемости составляют всего около 50%. В настоящей статье представлен анализ факторов развития резистентности к лечению лимфобластных лимфом и освещены современные стратегии терапии рецидивов/рефрактерных форм заболевания.

lymphoblastic lymphomarelapsechildrenimmunotherapyallogeneic hematopoietic stem cell transplantationлимфобластная лимфомарецидивдетииммунотерапияаллогенная трансплантация гемопоэтических стволовых клетокTemple W.C., Mueller S., Hermiston M.L., Burkhardt B. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults. Best Pract Res Clin Haematol 2023;36(1):101449.Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., Araujo I.B.O., Berti Е. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022;36(7): 1720–48.Cortelazzo S., Ponzoni M., Ferreri A.J., Hoelzer D. Lymphoblastic lymphoma. Crit Rev Oncol Hematol 2011;79(3):330–43.Burkhardt B., Hermiston M.L. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol 2019;185(6):1158–70.Devine K.J., Fries C., Hermiston M., Wistinghausen B. How I approach B-lymphoblastic lymphoma in children. Pediatr Blood Cancer 2023;70: e30401.Burkhardt B., Taj M., Garnier N., Minard-Colin V., Hazar V., Mellgren K. et al. Treatment and outcome analysis of 639 relapsed non-Hodgkin lymphomas in children and adolescents and resulting treatment recommendations. Cancers (Basel) 2021;13(9):2075.Cairo M.S., Beishuizen A. Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives. Br J Haematol 2019;185(6):1021–42.Iacobucci I., Mullighan C.G. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol 2017;35(9): 975–83.Ma X., Edmonson M., Yergeau D., Muzny D.M., Hampton O.A., Rusch M. et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun 2015;6:6604.Yang J.J., Bhojwani D., Yang W., Cai X., Stocco G., Crews K. et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 2008;112(10):4178–83.Delgado-Martin C., Meyer L.K., Huang B.J., Shimano K.A., Zinter M.S., Nguyen J.V. et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia 2017;31(12):2568–76.Schmidt S., Irving J.A., Minto L., Matheson E., Nicholson L., Ploner A. et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J 2006;20(14):2600–2.Mullighan C.G., Zhang J., Kasper L.H., Lerach S., Payne-Turner D., Phillips L.A. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011;471(7337):235–9.Meyer J.A., Wang J., Hogan L.E., Yang J.J., Dandekar S., Patel J.P. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 2013;45(3):290–4.Tzoneva G., Perez-Garcia A., Carpenter Z., Khiabanian H., Tosello V., Allegretta M. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 2013;19(3):368–71.Locatelli F., Shah B., Thomas T., Velasco K., Adedokun B., Aldoss I. et al. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review. Leuk Lymphoma 2023;64(10):1615–33.Shah N.N., Fry T.J. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 2019;16(6):372–85.Sotillo E., Barrett D.M., Black K.L., Bagashev A., Oldridge D., Wu G. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 2015;5(12):1282–95.Fischer J., Paret C., El Malki K., Alt F., Wingerter A., Neu M.A. et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother 2017;40(5):187–95.Braig F., Brandt A., Goebeler M., Tony H.P., Kurze A.K., Nollau P. et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 2017;129(1):100–4.Zoghbi A., Zur Stadt U., Winkler B., Müller I., Escherich G. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. Pediatr Blood Cancer 2017;64(11).Jacoby E., Nguyen S.M., Fountaine T.J., Welp K., Gryder B., Qin H. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun 2016;7:12320.Michaux K., Bergeron C., Gandemer V., Mechinaud F., Uyttebroeck A., Bertrand Y.; SFCE and the EORTC children leukemia group. Relapsed or refractory lymphoblastic lymphoma in children: results and analysis of 23 patients in the EORTC 58951 and the LMT96 protocols. Pediatr Blood Cancer 2016;63(7):1214–21.Burkhardt B., Reiter A., Landmann E., Lang P., Lassay L., Dickerhoff R. et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin–Frankfurt–Muenster group. J Clin Oncol 2009;27(20):3363–9.Gross T.G., Hale G.A., He W., Camitta B.M., Sanders J.E., Cairo M.S. et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphomain children and adolescents. Biol Blood Marrow Transpl 2010;16(2):223–30.Gökbuget N., Dombret H., Bonifacio M., Reichle A., Graux C., Faul C. et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018;131(14): 1522–31.Kantarjian H., Stein A., Gökbuget N., Fielding A.K., Schuh A.C., Ribera J.M. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376(9):836–47.Kaplan J.B., Grischenko M., Giles F.J. Blinatumomab for the treatment of acute lymphoblastic leukemia. Invest New Drugs 2015;33(6):1271–9.Locatelli F., Zugmaier G., Mergen N., Bader P., Jeha S., Schlegel P.G. et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J 2020; 10(7):77.Sadelain M., Brentjens R., Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3(4):388–98.Maude S.L., Laetsch T.W., Buechner J., Rives S., Boyer M., Bittencourt H. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378(5):439–48.Schuster S.J., Bishop M.R., Tam C.S., Waller E.K., Borchmann P., McGuirk J.P. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45–56.Fry T.J., Shah N.N., Orentas R.J., Stetler-Stevenson M., Yuan C.M., Ramakrishna S. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018;24(1): 20–8.Shor B., Gerber H.P., Sapra P. Preclinical and clinical development of inotuzumab ozogamicin in hematological malignancies. Mol Immunol 2015;67(2 Pt A):107–16.Rubinstein J.D., O'Brien M.M. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations. Front Immunol 2023;14:1237738.Kantarjian H.M., DeAngelo D.J., Stelljes M., Martinelli G., Liedtke M., Stock W. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375(8):740–53.Cohen M.H., Johnson J.R., Massie T., Sridhara R., McGuinn W.D. Jr, Abraham S. et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006;12(18): 5329–35.Leśniak M., Lipniarska J., Majka P., Lejman M., Zawitkowska J. Recent updates in venetoclax combination therapies in pediatric hematological malignancies. Int J Mol Sci 2023;24(23):16708.Pullarkat V.A., Lacayo N.J., Jabbour E., Rubnitz J.E., Bajel A., Laetsch T.W. et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 2021;11(6):1440–53.Bride K.L., Vincent T.L., Im S.Y., Aplenc R., Barrett D.M., Carroll W.L. et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 2018;131(9):995–9.Bhatla T., Hogan L.E., Teachey D.T., Bautista F., Moppett J., Velasco Puyó P. et al. Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood 2024;144(21):2237–47.De Smedt R., Morscio J., Reunes L., Roels J., Bardelli V., Lintermans B. et al. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood 2020;135(19): 1685–95.Gomes-Silva D., Srinivasan M., Sharma S., Lee C.M., Wagner D.L., Davis T.H. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 2017;130(3):285–96.Bayón-Calderón F., Toribio M.L., González-García S. Facts and challenges in immunotherapy for T-cell acute lymphoblastic leukemia. Int J Mol Sci 2020;21(20):7685.Pan J., Tan Y., Wang G., Deng B., Ling Z., Song W. et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol 2021;39(30): 3340–51.